SHARE

Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Delivers Strong 2022 Performance With 127% Sales Growth
25.03.2023

Porton Delivers Strong 2022 Performance With 127% Sales Growth

  • In 2022, Porton delivers RMB 7 billion revenue and 127% revenue growth.

  • Net profit attributable to shareholders of the listed company increased 283% to RMB 2 billion.

  • New POs of DP CDMO increased by 67% to RMB 119 million, and that of CGT CDMO increased by 25% to RMB 159 million

  • 2023 CAPEX is expected to remain at the level of RMB 1.4-1.7 billion
Porton Delivers Strong 2022 Performance With 127% Sales Growth

Chongqing, China, 25 March 2023 – Porton Pharma Solutions Ltd. (Stock Code: 300363) has reported record revenue of RMB 7 billion, growing 127% and net profit attributable to shareholders of the listed company of RMB 2 billion, growing 283%. These robust financial results are mainly driven by strong business performance and the delivery of the material purchase orders.

In 2022, Porton continued to increase its market development and achieved continuous introduction of customers and projects. Porton has a track record of more than 2200 projects of about 800 global customers. In 2022, API CDMO, as the company’s major business segment, provided services for approximately 300 customers and delivered 449 projects, including 28 process validation projects. Two new business segments, Drug Product CDMO and Cell and Gene Therapy CDMO received new product orders with the amount of RMB 119 million and 159 million respectively.

Porton maintained investment in R&D and manufacturing capacities and capabilities. The R&D investment increased by 96.92% to RMB 520 million and our R&D team expanded to 1,330 staff. The laboratory area is expected to exceed 50,000 square meters in 2023 as our largest R&D facility in Shanghai to start operation. The API CDMO manufacturing capacity has expanded to around 2,100 cubic meters. In 2022, the Company launched the construction of the process development and production site in Slovenia, its first R&D and production facility in Europe, to further expand its globalization layout and provide global services to customers. For DP CDMO, the first phase of the manufacturing site with three production workshops for solids and two for injections was put into use in 2022. For CGT CDMO, the industrial base in Suzhou was put into use in December, after which there are over 20,000 square meters of process development and production workshops for the CGT capacity with ten production lines of GMP viral vectors, 12 production lines of GMP cell therapy and hundreds of clean workshops.

Porton has announced 2023 CAPEX guidance to remain at the level of RMB 1.4-1.7 billion to continue capability construction, including manufacturing capacities, R&D facilities and strategic new capabilities such as peptides, Oligonucleotides, ADCs and biologics.

Oliver Ju, Chairman and CEO of Porton, commented, “2022 is an important milestone during Porton's 17 years history. Despite the challenging macro environment, Porton secured and successfully delivered its largest orders and achieved record performance in 2022. With the operational cash flows generated, Porton accelerated its capacity expansion and capability enhancement so as to realize its strategic goal to build an end-to-end global pharmaceutical service platform. ”

Moving into 2023, Porton enters a new three-year strategic cycle. By combining long-term and short-term goals, we will focus on six strategies which are "achieving breakthroughs in key business opportunities, developing new businesses, making breakthroughs in key technologies, marketing reform, digital transformation, and globalization." By achieving breakthroughs in key markets, key customers, and key products, Porton will continue to invest and transform its core business and organizational capabilities to enhance customer value and business competitiveness, as well as to maintain its long-term competitiveness. At the same time, we will continue to focus on operational efficiency, achieve cost savings and efficiency gains through innovation and transformation.



About Porton

Founded in 2005, Porton Pharma Solutions Ltd. is a global CDMO provides one-stop services for small molecule drugs, peptides, oligonucleotides, biologics and gene & cell therapy during the entire life cycle from preclinical research to drug approval for global pharmaceutical companies, biotechs, scientific research institutes, etc. We are committed to providing customers with excellent end-to-end CDMO services, enabling good medicines to benefit the public earlier. As of the end of 2022, Porton has established business relationships with almost 800 global customers and has delivered more than 2,200 projects.

With more than 5,000 employees worldwide, we have R&D centers, manufacturing facilities and sales offices across China, the United States, Slovenia, Belgium, Switzerland and Denmark.

Find out more at https://www.portonpharma.com/index.html

SHARE

Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Delivers Strong 2022 Performance With 127% Sales Growth
Driving innovation and excellence in the CDMO industry, Porton Pharma Solutions 2024 CPHI Europe Review Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals Porton Will Be Participating In Biotech Outsourcing Strategies Events This June Proton At CPhI North America Again Porton 2023 ESG Report Upcoming Porton Shows In Europe And The USA:Shaping Our Future Together Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development Join Our Founder And CEO @ DCAT Week Porton Pharma Solutions Joined The SBTi To Drive Climate Action Farewell To 2023, And WE Are Sailing Forward To 2024 The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia. Porton Gets Improved In The 2023 S&P Global ESG Score Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023 [Important Notice] Porton Announcement Regarding The Change Of Email Domain Porton Unveils Its Small Molecule Platform Headquarters In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai Porton At DCAT Week 2023: A Highly Successful And Strategic Event Porton Released 2022 CSR Report Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score
News

Insights Unveiled: Delve into Our Global News Hub!

22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš

Read the news

Cookie settings

Your current status

Show details